Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 15/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25908530 | 0.86 | CYP4F2 (0.39) | ATRCYP4F2CYP4A11 | |
| SCHEMBL25160408 | 0.85 | ATR (0.53) | ATR | |
| SCHEMBL25908700 | 0.83 | ATR (0.42) | ATRCYP4F2CYP4A11PIK3R1PIK3CA | |
| SCHEMBL25908532 | 0.81 | ATR (0.38) | ATRCYP4F2CYP4A11 | |
| SCHEMBL25908696 | 0.80 | MAP3K7 (0.44) | MAP3K7PIK3R1PIK3CA | |
| SCHEMBL25908818 | 0.79 | CYP4F2 (0.39) | ATRCYP4F2CYP4A11 | |
| SCHEMBL25908777 | 0.79 | ATR (0.43) | ATRCYP4F2CYP4A11 | |
| SCHEMBL30460631 | 0.78 | CYP4F2 (0.43) | ATRCYP4F2CYP4A11 | |
| SCHEMBL30662637 | 0.77 | CYP4F2 (0.36) | ATRCYP4F2CYP4A11 | |
| SCHEMBL31278690 | 0.77 | MAP3K7 (0.34) | ATRMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101040-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yayo Biotechnology Co., Ltd. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4467545-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yayo Biotechnology Co. Ltd (CN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023138343-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏亚尧生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101040-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, ATR, WEE2 | ATR 2/4885CYP4F2 225/4885CYP4A11 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.